Feedback plc (LSE:FBDK), once known chiefly for medical-imaging software, is today one of the London market's smallest healthcare-technology companies, valued at under £3m. Yet its clinical-communications platform, Bleepa, has quietly threaded itself into the plumbing of the National Health Service, from cancer pathways to …
Surgical Innovations Group (LSE:SUN) designs and manufactures instruments used in minimally invasive, or keyhole, surgery — the ports, graspers and hybrid reusable-disposable tools that surgeons rely on for laparoscopic operations. It is a genuinely small company: aMarket Valueof under £5m, a share price hovering …
TheraCryf plc (LSE:TCF) is a clinical-stage drug developer working on treatments for addiction and other brain disorders. Until April 2024 it was called Evgen Pharma; it rebranded after acquiring a new pipeline. It is genuinely tiny — a market value of around £4m and …
Imunon, Inc. (Nasdaq: IMNN), the former Celsion Corporation, is a clinical-stage biotechnology company developing DNA-based immunotherapies for cancer. Its lead candidate, IMNN-001, is in a pivotal Phase 3 trial in advanced ovarian cancer, and earlier data have been eye-catching. Yet the company is tiny: …
Oxford BioDynamics (LSE:OXB) is a British precision-medicine company that reads the three-dimensional structure of the genome to build diagnostic blood tests. Its EpiSwitch platform aims to detect and predict disease more accurately than conventional markers, with flagship products in prostate cancer screening and cancer …
IXICO PLC provides specialist neuroimaging and biomarker analytics for pharmaceutical, biotechnology and diagnostics customers developing treatments for neurological diseases. Its AI-driven platform supports the collection, management and analysis of imaging data used in clinical trials. The stock’s latest advance reflects improving confidence following stronger …
AIM-listed diagnostics company Renalytix (LSE:RENX) has delivered some of the strongest clinical validation in its history, yet its shares remain under significant pressure. On 30 June 2026, the group reported two-year real-world outcomes for its FDA-authorised KidneyIntelX.dkd test involving 2,470 patients with type 2 …
Allergy Therapeutics (LSE:AGY), the AIM-quoted immunotherapy specialist, delivered a confident set of full-year results for the 12 months ended 30 June 2026. Revenue rose 9% to £59.9 million, second-half sales increased by more than 12%, and cash more than doubled to £24.2 million following …
On 6 August 2026 Fusion Antibodies announced that the Australian patent office had accepted a patent covering its antibody-library technology, following a similar notice of allowance in Canada on 22 June 2026. For a company whose value ultimately rests on the strength and defensibility …
IXICO (LSE:IXI), the AIM-quoted neuroscience imaging and biomarker analytics group, lifted its full-year revenue guidance in July to at least 8.0 million pounds, implying growth of roughly 22%, yet its shares have since slipped back below both their 50-day and 200-day moving averages. The …